Phase II trial of Sorafenib combined with on-demand Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer stage C)

Phase II trial of Sorafenib combined with on-demand Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer stage C) - STAB study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014213

Enrollment

Registered

2014-06-10

Start date

2013-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced hepatocellular carcinoma

Interventions

Sorafenib with Transarterial chemoembolization

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hepatocellular carcinoma 2. First line systemic chemotherapy 3. BCLC stage C 4. ECOG PS 0, 1 5. Child Pugh A

Exclusion criteria

Exclusion criteria: 1. Tumor thrombus of main or first branch portal vein 2. Brain metastasis

Design outcomes

Primary

Measure	Time frame
Rate of complete a protocol treatment	—

Secondary

Measure	Time frame
Adverse event, Survival time, Tumor response	—

Countries

Japan

Contacts

Public ContactYozo Sato

Aichi Cancer Center Hospital Department of Diagnostic and Interventional Radiology

ysato@aichi-cc.jp052-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026